They are thrilled to have Helga, Karen, Dorothy, and Kerry join our board of directors. Their advice will direct strategic options, help Germfree seize opportunities, and help it overcome obstacles in the future. The Board will be essential in promoting long-term success and sustainable growth by utilizing their combined experience. The tale of Germfree is one of unrelenting invention, unshakable dedication to quality, and significant influence on world health. We’re still dedicated to pushing the boundaries of innovation and holding our top spot in cleanrooms, laboratories, and equipment for critical environments. According to Kevin Kyle, CEO of Germfree, Our Board will help Germfree capitalize on emerging trends and technological advancements, particularly in the rapidly evolving fields of cell and gene therapy.
Dorothy Puhy is well-known for her financial knowledge and offers a wealth of experience to the Germfree Board. She worked for the Dana Farber Cancer Institute for twenty-five years, finally becoming the Chief Operating Officer and Executive Vice President. She had a number of financial jobs at the Tufts – New England Medical Center Hospitals before becoming Chief Financial Officer. Before JNJ’s successful acquisition of Abiomed, Dorothy was a Lead Director there for about 20 years. In her capacity as a Lead Director at Abiomed, Dorothy collaborated extensively with the board members and the management group to establish the general direction and strategic goals. Dorothy was on the boards of BCBS, Azenta, and Reebok in addition to Abiomed. She spent many years as an adjunct faculty member at the Harvard School of Public Health.
Karen Flynn joins the Germfree board with over thirty years of experience in operations and sales. Her most recent position at Catalent was Interim President of BioModalities. Karen’s previous roles at Catalent were President of Biologics and Chief Commercial Officer. She was the Chief Commercial Officer and Senior Vice President of West Pharmaceutical Services before joining Catalent, where she also oversaw the company’s Pharmaceutical Packaging Systems division. In addition to her role on the Germfree board, Karen is presently a member of the boards of Sotera Health and Quanterix Corporation.
Veteran of the pharmaceutical industry Kerry Ingalls offers experience in both manufacturing and operations. In his prior role, he oversaw operations, corporate strategy planning, and the building, commissioning, and licensing of the CGT production facility at Poseida Therapeutics. Before joining Poseida, Kerry spent several years in a variety of leadership roles at Amgen. He was in charge of several operational sites and was in charge of all clinical and commercial GMP manufacturing at Amgen’s worldwide headquarters. Kerry served in the US Navy for a distinguished period of time before joining Amgen.
At Jacobs, Helga Salling is currently Vice President, Global Growth & Strategy-Life Sciences. Helga provides invaluable experience to the Germfree Board, having worked in the life sciences field for more than 20 years. Helga held positions at DPS Group and as COO at Advent Engineering prior to joining Jacobs. She was previously VP of Integrated Projects at IPS.
They are thrilled to have Helga, Karen, Dorothy, and Kerry join our board of directors. They contribute decades of expertise, strategic thinking, and leadership in important markets that Germfree services. According to Evis Hursever, Managing Director of EW Healthcare Partners and Chair of the Board of Directors, They are thrilled to be working with them as we aggressively scale the business to meet the needs of our customers, particularly in the cell and gene therapy space.
For more than 60 years, Germfree has established itself as a leading authority on state-of-the-art technology for cleanrooms, critical environments, and laboratories worldwide. Innovating cleanroom design and production for the biopharmaceutical, healthcare, and research industries, the company has continuously set the standard. Germfree is steadfast in its commitment to offering cutting-edge solutions that greatly increase patient access to treatments that can change their lives.
EW Healthcare Partners has generated more than $2 billion in cash since 2014 and is focused on making growth equity investments in rapidly expanding commercial-stage healthcare firms in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors in both the US and Europe. EW Healthcare Partners has demonstrated a steadfast dedication to the healthcare sector by investing over a long period of time in a wide range of healthcare firms across various industries, stages, and regions. The group’s operating partners, advisors, and senior investment professionals are situated in Houston, London, and New York.
